Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 248 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Looking back at a life-changing clinical trial September 16, 2022 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 Load more HOT NEWS Texting May Help Reduce Disparities in Colorectal Cancer Screening Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas
